Table 2.
Comparison of clinical manifestations between MDS patients with high and low global aberrant alternative splicing (AS) score
| Variables | Total | High aberrant AS score | Low aberrant AS score | P value |
|---|---|---|---|---|
| (n) | (n) | (n) | ||
| Sex a | 0.024* | |||
| Male | 121 | 87 | 34 | |
| Female | 55 | 30 | 25 | |
| Age (year) b | 69 (19–94) | 66 (19–89) | 73 (26–94) | 0.121 |
| ≧65 | 102 | 63 | 39 | |
| <65 | 74 | 54 | 20 | |
| Laboratory data b | ||||
| WBC (/μL) | 3825 (490–20440) | 3780 (490–20440) | 4660 (1710–11690) | 0.426 |
| Hb (g/dL) | 8.1 (3.5–14.6) | 8.1 (3.5–13.6) | 8.1 (3.7–14.6) | 0.792 |
| Platelet (×1000 /μL) | 85 (3–721) | 82 (9–721) | 106 (3–460) | 0.08 |
| Cytogenetics a | ||||
| Favorablec | 115 | 71 | 44 | 0.09 |
| Intermediated | 23 | 17 | 6 | 0.382 |
| Poore | 26 | 20 | 6 | 0.197 |
| Genetic alterations a | ||||
| SF3B1 | 29 | 17 | 12 | 0.342 |
| U2AF1 | 14 | 13 | 1 | 0.028* |
| SRSF2 | 24 | 15 | 9 | 0.675 |
| ZRSR2 | 15 | 12 | 3 | 0.254 |
| TET2 | 22 | 17 | 5 | 0.246 |
| ASXL1 | 36 | 26 | 10 | 0.386 |
| DNMT3A | 25 | 18 | 7 | 0.517 |
| EZH2 | 10 | 7 | 3 | 0.809 |
| IDH1/IDH2 | 4 | 4 | 0 | 0.151 |
| TP53 | 12 | 10 | 2 | 0.193 |
| RUNX1 | 25 | 18 | 7 | 0.517 |
*Statistically significant (P < 0.05)
aNumber of patients
bMedian (range)
cFavorable cytogenetics: -Y, del(11q), Normal, del(5q), del(12p), del(20q), double including del(5q)
dIntermediate-risk cytogenetics: del(7q), +8, +19, i(17q), any other single or double independent clones
ePoor-risk cytogenetics: −7, inv(3)/t(3q)/del(3q), double including −7/de(7q), complex: 3 abnormalities, complex: >3 abnormalities